Personalized therapies in pediatric inflammatory and autoimmune diseases

Gabriele Stocco, Sara de Iudicibus, Raffaella Franca, Riccardo Addobbati, Giuliana Decorti

Research output: Contribution to journalArticlepeer-review


Pediatric inflammatory and autoimmune diseases are a wide array of systemic or organ-specific conditions, characterized by an exaggerated immune reactivity, which generally occurs in immunogenetically predisposed children. Among the most important ones, in terms of their diffusion and morbidity in the population worldwide, pediatric inflammatory bowel disease (IBD) and juvenile rheumatoid arthritis (JRA) have to be considered. The aim of personalized therapy is to give to each patient the most appropriate drug and dose regimen, in order to maximize treatment response and reduce the risk of adverse events. In general, several therapeutic options exist for pediatric inflammatory and autoimmune conditions, therefore the perspective of pharmacological tools that allow identification of patients with increased risk of treatment issues related to a particular medication, in terms of lack of efficacy or increased probability of adverse events, is particularly desirable and promising. The present review will be focused on the personalized therapy approaches already available or in development for pediatric patients with IBD or JRA, comprising pharmacokinetic, pharmacodynamic and pharmacogenetic assays.

Original languageEnglish
Pages (from-to)5766-5775
Number of pages10
JournalCurrent Pharmaceutical Design
Issue number35
Publication statusPublished - 2012


  • Juvenile rheumatoid arthritis
  • Pediatric inflammatory bowel disease
  • Personalized therapy
  • Pharmacodynamics
  • Pharmacogenetics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Personalized therapies in pediatric inflammatory and autoimmune diseases'. Together they form a unique fingerprint.

Cite this